Stocks Health care FULC
NASDAQ · Health careFulcrum Therapeutics, Inc. (FULC)
It posted a net loss of $85M. In fiscal 2025 capital spending exceeded operating cash flow by $60.4M. At June 30, 2026 it held $48.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
Key facts about Fulcrum Therapeutics, Inc.
- Net worth
- Fulcrum Therapeutics, Inc. has a market value (market cap) of $283.8M at the latest share price, and shareholders' equity of $310.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $74.9M.
- Cash flow
- In fiscal 2025 operations used $60.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 30, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Fulcrum Therapeutics, Inc. does
Fulcrum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FULC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$74.9M | -$1.18 | -$60.4M |
| 2024 | $80M | -$9.7M | -$0.16 | -$2.5M |
| 2023 | $2.8M | -$97.3M | -$1.59 | -$91.5M |
| 2022 | $6.3M | -$109.9M | -$2.44 | -$99M |
| 2021 | $19.2M | -$80.8M | -$2.29 | -$80.2M |
| 2020 | $8.8M | -$70.8M | -$2.79 | -$55M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Fulcrum Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- October 28, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 20, 2026
- October 8, 2026
- September 2, 2026
- August 17, 2026Form 425 filing 425
- August 17, 2026Form 425 filing 425
- August 17, 2026Form 425 filing 425
- August 17, 2026
Insider trades
What the people running Fulcrum Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 17, 2026 | Tang Kevin10% owner | Boughtindirect | 50,945 | $179.3K |
| July 16, 2026 | Tang Kevin10% owner | Boughtindirect | 116,671 | $415.3K |
| July 15, 2026 | Tang Kevin10% owner | Boughtindirect | 107,377 | $382.3K |
| July 14, 2026 | Tang Kevin10% owner | Boughtindirect | 53,651 | $191K |
| July 14, 2026 | Tang Kevin10% owner | Boughtindirect | 75,952 | $271.9K |
| July 13, 2026 | Tang Kevin10% owner | Boughtindirect | 12,966 | $45.9K |
| June 26, 2026 | Ezekowitz AlanDirector | Soldpre-planned (10b5-1) | 18,000 | $65.6K |
| February 2, 2026 | Gould Robert JDirector | Soldpre-planned (10b5-1) | 15,000 | $160.9K |
Who owns FULC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tang Capital Management, LLC13G, passive with 5 related filers | 10.4% | July 15, 2026 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 9% | June 25, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 8.22% | August 14, 2026 |
| BlackRock Portfolio Management LLC13G, passive | 6% | July 17, 2026 |
| Montanova Capital, LLC13G, passive with 2 related filers | 5.5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 155 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 10,950,080 | +7,900,040 |
| BlackRock, Inc. | 8,824,259 | +3,433,666 |
| EcoR1 Capital, LLC | 6,549,866 | new |
| Tang Capital Management LLC | 6,521,412 | new |
| Montanova Capital, LLC | 3,680,921 | -2,880,190 |
| D. E. Shaw & Co., Inc. | 3,044,385 | +1,421,104 |
| Citadel Advisors LLC | 2,704,505 | +1,412,019 |
| Vanguard Capital Management LLC | 2,697,216 | +4,268 |
| Jane Street Group, LLC | 2,217,498 | +1,907,081 |
| State Street Corp | 2,037,025 | +487,174 |
| Adage Capital Partners GP, L.L.C. | 2,000,000 | +1,600,000 |
| GSK plc | 1,785,714 | 0 |
| Qube Research & Technologies Ltd | 1,748,467 | +773,728 |
| Assenagon Asset Management S.A. | 1,670,408 | +476,535 |
| Renaissance Technologies LLC | 1,647,800 | +1,634,200 |
| ADAR1 Capital Management, LLC | 1,565,029 | +1,434,469 |
| Millennium Management LLC | 1,485,803 | +1,129,332 |
| Geode Capital Management, LLC | 1,432,133 | -54,409 |
| Marshall Wace, Llp | 1,358,423 | new |
| UBS Group AG | 1,253,909 | +938,724 |
Insiders
5 insiders reported holding 13,610,948 shares in total, about $50.6M at the last price.
| Holder | Shares |
|---|---|
| Tang Kevin10% owner | 7,080,9457,080,945 held indirectly |
| Ra Capital Management, L.P.10% owner | 6,053,9606,053,960 held indirectly |
| Gould Robert JDirector | 454,864 |
| Ezekowitz AlanDirector | 10,927 |
| Oltmans Curtis GaleChief Legal Officer | 10,252 |
Questions about FULC
What does Fulcrum Therapeutics, Inc. do?
Fulcrum Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as FULC. Its shares trade on NASDAQ under the ticker FULC.
What is Fulcrum Therapeutics, Inc.'s net worth?
Fulcrum Therapeutics, Inc. has a market value (market cap) of $283.8M at the latest share price, and shareholders' equity of $310.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Fulcrum Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $85M.
When did Fulcrum Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration (amended) from November 3, 2026.
Similar companies
Compare FULC with
Follow FULC
Get an email when Fulcrum Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Fulcrum Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.